Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma

Trial Profile

Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Rigosertib (Primary) ; Cisplatin
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 14 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top